

## Prof. LEYLA OZER



### Personal Information

Office Phone: [+90 212 404 4553](tel:+902124044553)

Email: [leyla.ozer@acibadem.edu.tr](mailto:leyla.ozer@acibadem.edu.tr)

Web: <https://avesis.acibadem.edu.tr/100047>

### International Researcher IDs

ORCID: 0000-0003-4092-5051

Yoksis Researcher ID: 167587



### Education Information

Post Doctorate of Medicine, Istanbul University, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Turkey 2009 - 2013

Expertise In Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 2002 - 2008

### Academic Titles / Tasks

Associate Professor, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2015 - Continues

Assistant Professor, Fırat University, School Of Medicine, Department Of Internal Medicine, 2014 - 2015

### Academic and Administrative Experience

Staj Koordinatörü, Acibadem Mehmet Ali Aydınlar University, School Of Medicine, Department Of Medical Sciences, 2018 - Continues

### Courses

Geriatrik meme kanseri hasta yönetimi , Postgraduate, 2021 - 2022

Meme Kanseri Hastada Beslenme ve Nutrisyon , Postgraduate, 2021 - 2022

Onkolojiye Giriş ( Etyoloji, Tanı, Evreleme, Tedavi), Undergraduate, 2014 - 2015, 2013 - 2014

Kemoterapi İlaçları ve Toksikiteği , Undergraduate, 2014 - 2015, 2013 - 2014

Onkolojik Acillere Yaklaşım, Undergraduate, 2014 - 2015, 2013 - 2014

Kanser Ağrısına Yaklaşım ve Destek Tedavisi , Undergraduate, 2014 - 2015, 2013 - 2014

Sık Görülen Kanselerler, Undergraduate, 2014 - 2015, 2013 - 2014

Paraneoplastik Sendromlar, Undergraduate, 2014 - 2015, 2013 - 2014

Anjiyogenez ve Metastaz, Undergraduate, 2013 - 2014

Lenfoma, Undergraduate, 2013 - 2014

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study**  
ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., Uslu R., Mandel N. M., YALÇIN Ş., Teomete M., et al.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, no.5, pp.562-568, 2024 (SCI-Expanded)
- II. **Contemporary results from the PelvEx collaborative: improvements in surgical outcomes for locally advanced and recurrent rectal cancer**  
Fahy M., Kelly M. E., Abecasis N., Akhtar S. N., Akiyoshi T., Alvarez-Gallego M., Andric M. D., Arteaga-Asensio P., Assi H., Austin K. K., et al.  
COLORECTAL DISEASE, no.5, pp.926-931, 2024 (SCI-Expanded)
- III. **Case Report: Chemoimmunotherapy in microsatellite-instability-high advanced goblet cell carcinoma of the colon**  
Mutlu A. U., Aytaç E., Gulmez M., Erdamar Çetin A. S., Ozer L.  
FRONTIERS IN IMMUNOLOGY, 2023 (SCI-Expanded)
- IV. **Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm**  
Aktas M. K., AYTAÇ E., YILDIZ İ., OZER L.  
The Lancet Oncology, vol.24, no.5, 2023 (SCI-Expanded)
- V. **Current trends in perioperative treatment of resectable gastric cancer.**  
Yıldız İ., Özer L., Şenocak Taşçı E., Bayoğlu İ. V., Aytac E.  
World journal of gastrointestinal surgery, vol.15, no.3, pp.323-337, 2023 (SCI-Expanded)
- VI. **Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement**  
Aytaç E., Özer L., Baca B., Balık E., Kapran Y., Taşkın O. C., Oyan Uluç B., Abacıoğlu M. U., Gönenç M., Bölükbaşı Y., et al.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.8, pp.627-663, 2022 (SCI-Expanded)
- VII. **Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study**  
Tasci E. S., Oyan B., Sonmez O., Mutlu A. U., Atci M. M., Oner I., Cinkir H. Y., Eryilmaz M. K., Balcik O. Y., Paksoy N., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.4, 2022 (SCI-Expanded)
- VIII. **Intramural Component of Venous, Lymphatic, and Perineural Invasion in Colon Cancer: A Threat or an Illusion?**  
Özer L., Taşçı E. Ş., Mutlu A. U., Piyade B., Ramoğlu N., Ajredini M., Gürleyik D., Çeçen R., Dinçer S. N., Musevitoğlu T., et al.  
BALKAN MEDICAL JOURNAL, vol.39, no.6, pp.436-443, 2022 (SCI-Expanded)
- IX. **Clinicopathological and Prognostic Significance of MSI Status and PD-L1 Expression in Turkish Patients with Gastric Cancer**  
Bahsi S., YILDIZ İ., Erdamar S., Goksel S., Tozun N., AYTAÇ E., Demir G., ER O., BACA B., KARAHASANOĞLU T., et al.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.4, pp.246-254, 2021 (SCI-Expanded)
- X. **Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group**  
AYTAÇ E., Aslan F., ÇİÇEK B., Erdamar S., Gurses B., GÜVEN K., Falay O., KARAHASANOĞLU T., Selcukbiricik F., Selek U., et al.  
TURKISH JOURNAL OF GASTROENTEROLOGY, no.7, pp.584-598, 2019 (SCI-Expanded)
- XI. **The expression levels of miRNA-15a and miRNA-16-1 in circulating tumor cells of patients with diffuse large B-cell lymphoma**  
TUNÇER Ş. B., AKDENİZ ÖDEMİŞ D., ÇELİK B., KILIÇ ERCİYAS S., Sukruoglu O., Avsar M., Ozer L., EKENEL M., Ozel S., YAZICI H.  
MOLECULAR BIOLOGY REPORTS, vol.46, no.1, pp.975-980, 2019 (SCI-Expanded)
- XII. **Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.**  
Yildiz İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A., Akman T., Bayoğlu I., UYSAL M., Yildiz Y., et al.  
Tumori, vol.104, no.6, pp.444-450, 2018 (SCI-Expanded)
- XIII. **Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk**

**extremity soft tissue sarcoma: a single-institution experience.**

Kılıç L., Ekenel M., Karabulut S., Ağaoğlu F., Darendeliler E.

Contemporary oncology (Poznan, Poland), vol.21, pp.60-65, 2017 (SCI-Expanded)

- XIV. **Clinical significance of serum interleukin-17 levels in colorectal cancer patients**  
KARABULUT S., Afsar C. U., Karabulut M., Kilic L., Alis H., Kones O., Bilgin E., Aykan N. F.  
JOURNAL OF BUON, vol.21, no.5, pp.1137-1145, 2016 (SCI-Expanded)
- XV. **Current adjuvant treatment modalities for gastric cancer: From history to the future**  
Kilic L., Ordu C., Yildiz İ., Sen F., Keskin S., Ciftci R., Pilanci K. N.  
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol.8, no.5, pp.439-449, 2016 (SCI-Expanded)
- XVI. **Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer**  
TAŞ F., YILDIZ İ., Kilic L., Ciftci R., Keskin S., Sen F.  
AMERICAN JOURNAL OF THERAPEUTICS, vol.23, no.3, 2016 (SCI-Expanded)
- XVII. **Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma**  
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., KARANLIK H., Kurul S., VATANSEVER S., ORAL E. N., et al.  
JOURNAL OF DERMATOLOGICAL TREATMENT, vol.27, no.3, pp.275-277, 2016 (SCI-Expanded)
- XVIII. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**  
Sen F., Yildiz İ., Odabas H., Tambas M., Kilic L., Karadeniz A., Altun M., Ekenel M., Serilmez M., Duranyildiz D., et al.  
TUMOR BIOLOGY, vol.36, no.2, pp.1039-1044, 2015 (SCI-Expanded)
- XIX. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients**  
Kilic L., YILDIZ İ., Sen F. K., Erdem M. G., SERİLMEZ M., Keskin S., Ciftci R., KARABULUT S., Ordu C., DURANYILDIZ H. D., et al.  
CANCER BIOMARKERS, vol.15, no.4, pp.405-411, 2015 (SCI-Expanded)
- XX. **Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.**  
Yildiz İ., Varol U., Sen F., Kilic L.  
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, vol.14, no.7, pp.654-6, 2014 (SCI-Expanded)
- XXI. **The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.**  
TAŞ F., KARABULUT S., Ciftci R., YILDIZ İ., Keskin S., Kilic L., Disci R.  
Japanese journal of clinical oncology, vol.44, no.8, pp.705-10, 2014 (SCI-Expanded)
- XXII. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.**  
Ciftci R., TAŞ F., TILGEN YASASEVER C., Aksit E., KARABULUT S., Sen F., Keskin S., Kilic L., YILDIZ İ., Bozbey H. U., et al.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.35, no.7, pp.6941-8, 2014 (SCI-Expanded)
- XXIII. **Coagulation tests show significant differences in patients with breast cancer**  
TAŞ F., Kilic L., DURANYILDIZ H. D.  
TUMOR BIOLOGY, vol.35, no.6, pp.5985-5992, 2014 (SCI-Expanded)
- XXIV. **Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up**  
ELİTOK A., Oz F., Cizgici A. Y., Kilic L., Ciftci R., Sen F., BUĞRA M. Z., MERCANOĞLU F., ÖNCÜL A., Oflaz H.  
CARDIOLOGY JOURNAL, vol.21, no.5, pp.509-515, 2014 (SCI-Expanded)
- XXV. **Aspirin resistance in patients with impaired renal functions**  
Aksu H. U., Oner E., Erturk M., Aksu H., Isiksacan N., Ozalp B., Akture G., Akbay E., Ozer L., Erol M. K.  
KARDIOLOGIA POLSKA, vol.72, no.4, pp.331-338, 2014 (SCI-Expanded)
- XXVI. **Age is a prognostic factor affecting survival in lung cancer patients**  
TAŞ F., Ciftci R., Kilic L., KARABULUT S.  
ONCOLOGY LETTERS, vol.6, no.5, pp.1507-1513, 2013 (SCI-Expanded)

- XXVII. **Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.**  
TAŞ F., Sen F., Odabas H., Kilic L., Keskin S., YILDIZ İ.  
International journal of clinical oncology, vol.18, no.5, pp.839-46, 2013 (SCI-Expanded)
- XXVIII. **Serum M65 as a biomarker for metastatic renal cell carcinoma.**  
YILDIZ İ., Sen F., Kilic L., Keskin S., DURANYILDIZ H. D., Bilgin E., Disci R., EKENEL M., Darendeliler E., Bavbek S., et al.  
Clinical genitourinary cancer, vol.11, no.3, pp.290-6, 2013 (SCI-Expanded)
- XXIX. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**  
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)
- XXX. **Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.**  
Sen F., Yildiz İ., Başaran M., Ekenel M., Oz F., Kilic L., Toz B., Gurdal A., Camlica H., Bavbek S., et al.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.18, no.3, pp.775-81, 2013 (SCI-Expanded)
- XXXI. **Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS)**  
TAŞ F., AYDOĞMUŞ ŞEN F., Keskin S., Kilic L.  
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol.27, no.6, pp.789-792, 2013 (SCI-Expanded)
- XXXII. **Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).**  
Keskin S., YILDIZ İ., AYDOĞMUŞ ŞEN F., AYDOĞAN F., Kilic L., EKENEL M., Saglam S., ŞAKAR B., Disci R., Aykan F.  
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.15, no.5, pp.403-8, 2013 (SCI-Expanded)
- XXXIII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.**  
Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoglu M., Igci A.  
Medical oncology (Northwood, London, England), vol.30, no.1, pp.354, 2013 (SCI-Expanded)
- XXXIV. **Clinical and prognostic significance of coagulation assays in lung cancer**  
TAŞ F., Kilic L., SERİLMEZ M., Keskin S., Sen F., DURANYILDIZ H. D.  
RESPIRATORY MEDICINE, vol.107, no.3, pp.451-457, 2013 (SCI-Expanded)
- XXXV. **Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.**  
TAŞ F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., YILDIZ İ., Yasasever V.  
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.23, no.2, pp.276-81, 2013 (SCI-Expanded)
- XXXVI. **Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?**  
Kilic L., Ordu C., EKENEL M., YILDIZ İ., Keskin S., Sen F., Gural Z., Asoglu O., KIZIR A., Aykan F.  
Medical oncology (Northwood, London, England), vol.30, no.3, pp.660, 2013 (SCI-Expanded)
- XXXVII. **Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?**  
AYDINER A., Ciftci R., KARABULUT S., Kilic L.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.10, pp.6109-6114, 2013 (SCI-Expanded)
- XXXVIII. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.**  
Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.  
Medical oncology (Northwood, London, England), vol.30, no.3, pp.679, 2013 (SCI-Expanded)
- XXXIX. **Clinical and prognostic significance of coagulation assays in melanoma.**  
TAŞ F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., YILDIZ İ., Yasasever V.  
Melanoma research, vol.22, no.5, pp.368-75, 2012 (SCI-Expanded)
- XL. **The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of**

### **serum CEA levels**

ŞANLI Y., KUYUMCU S., ÖZKAN Z. G., Kilic L., Balik E., TÜRKMEN C., HAS ŞİMŞEK D., IŞIK E. G., Asoglu O., Kapran Y., et al.

ANNALS OF NUCLEAR MEDICINE, vol.26, no.7, pp.551-558, 2012 (SCI-Expanded)

**XLI. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.**

TAŞ F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., YILDIZ İ.

Oncology, vol.81, no.5-6, pp.353-8, 2011 (SCI-Expanded)

**XLII. Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.**

Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Baybek S.

Onkologie, vol.34, no.11, pp.630-3, 2011 (SCI-Expanded)

## **Articles Published in Other Journals**

**I. False-positive MRI Findings in Breast Cancer After Neoadjuvant Chemotherapy and Correlation Between Tumor Response Patterns and HER2 Status**

Avdan Aslan A., Erdemli S., ERDOĞDU İ. H., Gultekin S., URAS C., Tokat F., ARICAN A., ÖZER L., Behzatoglu K., Meydan N., et al.

ACTA ONCOLOGICA TURCICA, vol.56, no.2, pp.97-105, 2023 (Peer-Reviewed Journal)

**II. The technical details of robotic-assisted mitral valve replacement**

GÜLLÜ A. Ü., SENAY S., Ersin E., KOÇYİĞİT M., OZER L., ÇELİK Ö., ALHAN C.

Journal of Visualized Surgery, vol.9, 2023 (Scopus)

**III. Impact of Professional Seniority on Total Neoadjuvant Treatment Approach for Locally Advanced Rectal Cancer**

Şenocak Taşçı E., AYTAÇ E., Ajredini M., Mutlu A. U., YILDIZ İ., OZER L.

Journal of Oncological Science, vol.9, no.2, pp.89-96, 2023 (Scopus)

**IV. The Youngest Patient with Metastatic Leiomyosarcoma of the Pancreas.**

Saka D., Şişman G., Özer L., Şahin D., Ceyhan G.

Journal of gastrointestinal cancer, vol.51, pp.722-723, 2020 (ESCI)

**V. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma**

KARABULUT S., Afsar Ç. U., Karabulut M., Alış H., Kılıc L., Çikot M., Yasasever C. T., Aykan N. F.

Journal of Gastrointestinal Cancer, vol.47, no.1, pp.47-54, 2016 (Scopus)

**VI. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience**

Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., Demirci S., Icli F., Onur H., SAİP P. M., et al.

JOURNAL OF BREAST HEALTH, vol.10, no.4, pp.209-215, 2014 (ESCI)

**VII. Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.**

YILDIZ İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.

Korean journal of urology, vol.55, no.1, pp.74-6, 2014 (Peer-Reviewed Journal)

**VIII. Clinical and prognostic significance of coagulation assays in gastric cancer**

TAŞ F., Ciftci R., Kilic L., SERİLMEZ M., KARABULUT S., Duranyildiz D.

Journal of Gastrointestinal Cancer, vol.44, no.3, pp.285-292, 2013 (Scopus)

**IX. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.**

TAŞ F., Sen F., Keskin S., Kilic L., YILDIZ İ.

Molecular and clinical oncology, vol.1, no.4, pp.788-792, 2013 (Peer-Reviewed Journal)

**X. Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma**

TAŞ F., KARABULUT S., Bilgin E., Kılıc L., Ciftci R., Duranyildiz D.

Journal of Gastrointestinal Cancer, vol.44, no.4, pp.404-409, 2013 (Scopus)

## Books & Book Chapters

### I. ADJUVANT CHEMOTHERAPY FOR HER2-NEGATIVE EARLY STAGE BREAST CANCER

Ozer L., Aydiner A.

in: BREAST CANCER - A GUIDE TO CLINICAL PRACTICE , ADNAN AYDINER,ATILLA SORAN,ABDULLAH IGCI, Editor, Springer, London/Berlin , Geneve, pp.357-383, 2019

## Refereed Congress / Symposium Publications in Proceedings

### I. Karaciğer Metastazı Olan Evre IV Kolorektal Kanser Hastalarının Küratif Tedavisinin Planlanmasında Multidisipliner Tümör Konseyi Kararlarının Etkisi

Cakcak İ. E., Aytaç E., Özben V., Özer L., Yıldız İ., Gönenç M., Ceyhan G. O., Karahasanoğlu T., Hamzaoğlu İ. H.

22. Ulusal Cerrahi Kongresi, Antalya, Turkey, 23 - 27 March 2022, pp.10

### II. Positive MRI findings in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy

Erdemli S., Taşkın F., Erdoğan İ. H., Tokat F., Behzatoğlu K., Meydan N., Ozer L., Arıcan A., Uras C.

European Congress of Radiology, Vienna, Austria, 3 - 07 March 2021, pp.164-165

### III. Clinicopathological and prognostic significance of microsatellite instability (MSI) status and PDI-1 expression in Turkish patients with gastric cancer.

Yıldız İ., Bahsi S., Erdamar S., Goksel S., Demir G., Er O., Baca B., Karahasanoğlu T., Hamzaoğlu İ. H., Arıcan A., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37

### IV. Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.

Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., KARANLIK H., Kurul S., VATANSEVER S., SAİP P. M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

### V. Distribution and frequency of BRCA gene mutations in Turkish population including Balkan Turks

Akdeniz D., Tuncer B. S., Kilic S., Sukruoglu O., Kilic L., Altundag K., Ciftci R., Ozel S., KARABULUT S., EKENEL M., et al.

AACR Special Conference on Cancer Susceptibility and Cancer Susceptibility Syndromes, California, United States Of America, 29 January - 01 February 2014, vol.74

### VI. Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.

Ciftci R., TAŞ F., Aksit E., VATANSEVER S., KARABULUT S., Sen F., Yıldız İ., Keskin S., Bozbey H. U., Kilic L., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32

### VII. Serum inflammatory parameters as prognostic factors in patients with gastric cancer: Is serum albumin the best inflammatory biomarker predicting prognosis?

Sen F., Zobaci E., Erdemli H. K., Kocabas R., Kilic L., Yildiz İ.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32

### VIII. Clinical and pathologic characteristics of ovarian cancer patients with BRCA1 and BRCA2 mutations in Turkish population

SAİP P. M., Akdeniz B., Tuncer B., Kilic S., Sukruoglu O., Altundag K., Kilic L., Ciftci R., Yazici H.

50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 30 May - 03 June 2014, vol.32

### IX. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma

KARABULUT S., Aykan N. F., Yıldız İ., Kilic L., Sen F., VATANSEVER S.

Gastrointestinal Cancers Symposium, San-Francisco, Costa Rica, 16 - 18 January 2014, vol.32

### X. Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on

### **progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?**

BAŞARAN M., Yildiz İ., Sen F., Kilic L., Keskin S., Darendeliler E., Bavbek S. E.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

### **XI. Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy**

Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., EKENEL M., Aykan N. F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

### **XII. Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.**

Ciftci R., Keskin S., KARABULUT S., Yildiz İ., Kilic L., Sen F., TAŞTEKİN D., TAŞ F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

### **XIII. Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.**

KARABULUT S., Kilic L., Ciftci R., Yildiz İ., Sen F., Keskin S., TAŞTEKİN D., TAŞ F.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

### **XIV. Berrak Hücreli Sarkom Bir olgu nedeniyle**

GÜRAL Z., OSKEROĞLU S., ERGÜN S., KILIÇ L., AKGÜN Z., YÜCEL S., KAYTAN SAĞLAM E.

20. Ulusal Kanser Kongresi, Turkey, 19 - 23 April 2013

## **Tasks In Event Organizations**

Aytaç E., Ozer L., Advances in gastrointestinal cancer care , Scientific Congress, İstanbul, Turkey, Nisan 2024

## **Metrics**

Publication: 80

Citation (WoS): 715

Citation (Scopus): 736

H-Index (WoS): 14

H-Index (Scopus): 14

## **Congress and Symposium Activities**

WEBTARGED, Invited Speaker, İstanbul, Turkey, 2024

AVOD ONKOLOJİ GÜNLERİ, Invited Speaker, Eskişehir, Turkey, 2023

Webtarged, Invited Speaker, İstanbul, Turkey, 2022

Türk Tıbbi Onkoloji Kongresi , Invited Speaker, Girne, Cyprus (Kktc), 2022

Biyobelirteçler Ve Onkolojik Tedaviler Sempozyumu, Invited Speaker, İstanbul, Turkey, 2022

Hedef Kanser 2022 , Invited Speaker, Girne, Cyprus (Kktc), 2022

On Targed Master Oncology , Invited Speaker, Antalya, Turkey, 2022

Immunooncology Network Meeting , Invited Speaker, İstanbul, Turkey, 2021

ulusal akciğer sağlığı kongresi , Invited Speaker, Antalya, Turkey, 2021

Kanserde İmmünoonkolojik ve Moleküler Onkolojik tedaviler Kursu , Invited Speaker, İstanbul, Turkey, 2021

HEDEF KANSER 2021 , Invited Speaker, Antalya, Turkey, 2021